Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV1.SIRT3-myc
- Development stage
- Preclinical
- Modality
- Gene Therapies
- Administration
- Intracerebral
01
Overview
AAV1.SIRT3-myc is an **adeno-associated virus serotype 1 gene therapy** designed to overexpress **sirtuin 3** in target tissues, with a **myc epitope tag** used for experimental detection of transgene expression. Based on the cited Parkinson's disease preclinical study, the construct was administered in a rat alpha-synuclein pre-formed fibril seeding model, where rAAV1.SIRT3-myc reduced alpha-synuclein inclusion burden, supporting a disease-modifying rationale in **Parkinson's disease**. Its intended mechanism is restoration or augmentation of mitochondrial SIRT3 deacetylase activity to improve mitochondrial function and counter pathogenic alpha-synuclein aggregation. The available evidence appears preclinical and research-stage rather than clinical or commercial, and no clear commercial developer or marketed product name is identifiable from the provided source alone.
- Other names
- AAV1 SIRT3 mycAAV-1 SIRT3 mycAAV 1 SIRT3 mycAAV vector encoding SIRT3-myc
02
Targets
SIRT3 (NAD-dependent protein deacetylase sirtuin-3)
Beyond the preview
Go deeper on AAV1.SIRT3-myc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV1.SIRT3-myc.